Skip to main content
TipRanks
Go Ultimate75% OFF

Solvonis Therapeutics (J4I) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Solvonis Therapeutics has a market cap or net worth of EUR 8.52M. The enterprise value is EUR 11.32M.

Market Cap
EUR 8.52M
Enterprise Value
EUR 11.32M

Share Statistics

Solvonis Therapeutics has 7,899,737,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
7,899,737,000
Owned by Insiders
5.26%
Owned by Institutions
―

Financial Efficiency

Solvonis Therapeutics’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is -48.94%.

Return on Equity (ROE)
-0.93
Return on Assets (ROA)
-0.76
Return on Invested Capital (ROIC)
-48.94%
Return on Capital Employed (ROCE)
-0.49
Revenue Per Employee
0
Profits Per Employee
-956.67K
Employee Count
6
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Solvonis Therapeutics is -1.10. Solvonis Therapeutics’s PEG ratio is -0.01.

PE Ratio
-1.10
PS Ratio
0.00
PB Ratio
1.27
Price to FCF
-2.06
Price to Operating Cash Flow
-1.87
PEG Ratio
-0.01

Income Statement

In the last 12 months, Solvonis Therapeutics had revenue of 0 and earned -5.74M in profits. Earnings per share was -0.00.

Revenue
0
Gross Profit
0
Operating Income
-3.48M
Pretax Income
-5.74M
Net Income
-5.74M
EBITDA
-5.74M
Earnings Per Share (EPS)
-0.00

Cash Flow

In the last 12 months, operating cash flow was -3.27M and capital expenditures 0, giving a free cash flow of -3.27M billion.

Operating Cash Flow
-3.27M
Free Cash Flow
-3.27M
Free Cash Flow per Share
-0.00

Dividends & Yields

Solvonis Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-48.51%
Earnings Yield
-90.70%

Stock Price Statistics

Beta
-2.13
52-Week Price Change
-92.81%
50-Day Moving Average
―
200-Day Moving Average
―
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Solvonis Therapeutics upcoming earnings date is Jun 30, 2027, TBA (Not Confirmed).

Last Earnings Date
Sep 30, 2026
Next Earnings Date
Jun 30, 2027
Ex-Dividend Date
―

Financial Position

Solvonis Therapeutics as a current ratio of 4.00, with Debt / Equity ratio of 1.21%

Current Ratio
4.00
Quick Ratio
4.00
Debt to Market Cap
0.00
Net Debt to EBITDA
0.29
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Solvonis Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Solvonis Therapeutics EV to EBITDA ratio is -1.93, with an EV/FCF ratio of -1.88.

EV to Sales
0.00
EV to EBITDA
-1.93
EV to Free Cash Flow
-1.88
EV to Operating Cash Flow
-1.88

Balance Sheet

Solvonis Therapeutics has EUR 1.72M in cash and marketable securities with EUR 75.00K in debt, giving a net cash position of EUR 1.65M billion.

Cash & Marketable Securities
EUR 1.72M
Total Debt
EUR 75.00K
Net Cash
EUR 1.65M
Net Cash Per Share
EUR 0.00
Tangible Book Value Per Share
EUR 0.00

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%